Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo E Diaz, MD, Matthew James Butler, MD, Anand Karnad, MD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 1592.

https://doi.org/10.1182/blood-2019-124382

Published: 2019

Journal Articles

Cyclic-AMP Is an Actionable Novel Regulator of PD-L1 Expression in Untransformed Lymphocytes and Diffuse Large B Cell Lymphomas

Binu Sasi, PhD, Zhijun Qiu, PhD, Shoulei Jiang, PhD, An-Ping Lin, MD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 3962.

https://doi.org/10.1182/blood-2019-123155

Published: 2019

Journal Articles

Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies

Jeffrey D. Cooney, Ricardo C. T. Aguiar

Blood (2016) 128 (25): 2886–2890.

https://doi.org/10.1182/blood-2016-09-737676

Published: 2016

Journal Articles

Synergism Between PDE4 and PI3Kδ Inhibitors in DLBCL: Improved Clinical Activity with the Potential for Lower Toxicity

Jeffrey Cooney, Long Wang, MD, An-Ping Lin, MD, Daifeng Jiang, PhD, Avvaru Suhasini, PhD, Ricardo C Aguiar, MD PhD

Blood (2016) 128 (22): 2938.

https://doi.org/10.1182/blood.V128.22.2938.2938

Published: 2016

Journal Articles

A Phosphodiesterase 4B-Mediated Interplay Between Tumor Cells and the Microenvironment Regulates Angiogenesis in B Cell Lymphoma

Avvaru Suhasini, Long Wang, Kenneth Holder, An-Ping Lin, Sang-Woo Kim, Harshita Bhatnagar, August Moritz, Ricardo C Aguiar, MD PhD

Blood (2015) 126 (23): 463.

https://doi.org/10.1182/blood.V126.23.463.463

Published: 2015

Journal Articles

PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes

Ali N. Chamseddine, MD, Yue Wei, PhD, Monica Cabrero, MD, Irene Ganan-Gomez, PhD MSc, Simona Colla, PhD, Koichi Takahashi, MD, Hui Yang, MD PhD, Marcos R Estecio, PhD, Zachary S. Bohannan, MA, Sherry Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD, Hagop M Kantarjian, MD, Elias Jabbour, Guillermo Garcia-Manero, MD

Blood (2015) 126 (23): 5227.

https://doi.org/10.1182/blood.V126.23.5227.5227

Published: 2015

Journal Articles

PDE4 Inhibitors Block TLR7 and TLR9-Driven Signaling, Proliferation and Cytokine Secretion in CLL Cells As Well As Proliferation Driven by Exposure to Apoptotic Cells

Ying Tan, M.D., Ph.D., Amanda A. Watkins, Ian R. Rifkin, M.D., Ph.D., Adam Lerner, MD

Blood (2012) 120 (21): 1774.

https://doi.org/10.1182/blood.V120.21.1774.1774

Published: 2012

Journal Articles

PDE4 Inhibitors Enhance DNA Damage-Induced Apoptosis In CLL

John Meyers, PhD, Adam Lerner, MD

Blood (2010) 116 (21): 2902.

https://doi.org/10.1182/blood.V116.21.2902.2902

Published: 2010

Journal Articles

Control of the PI3K/AKT Pathway by Phosphodiesterase 4B Modulates Glucocorticoid Response in B-Cell Lymphomas.

Sang-Woo Kim, PhD, Deepak Rai, PhD, Ricardo C Aguiar, MD, PhD,

Blood (2009) 114 (22): 728.

https://doi.org/10.1182/blood.V114.22.728.728

Published: 2009

Journal Articles

Phosphodiesterase-4 Inhibition Reduces Ischemic/Reperfusion Liver Injury in a Mouse Model for Sickle Cell Disease.

Alida Filippini, Giorgio Malpeli, Anne Janin, Orah S Platt, Christhope Leboeuf, Aldo Scarpa, Yves Beuzard, Lucia De Franceschi, MD

Blood (2008) 112 (11): 1444.

https://doi.org/10.1182/blood.V112.11.1444.1444

Published: 2008

Journal Articles

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

J. Brice Weinberg, MD, Ning Jiang, MD, Alicia D. Volkheimer, MS, Youwei Chen, MD, Karen M. Bond, BS, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Carlos M. de Castro, MD, David A. Rizzieri, MD, PhD, Marc C. Levesque, MD, PhD, Kenneth Mugridge, PhD, Joe DeAngelo

Blood (2007) 110 (11): 3129.

https://doi.org/10.1182/blood.V110.11.3129.3129

Published: 2007

Journal Articles

PDE4 Inhibitors Augment Glucocorticoid Receptor Levels in B-CLL Cells but Not in T Cells, B Cells, Monocytes or Neutrophils.

Adam Lerner, MD, John A. Meyers, BA, Josephine A. Taverna, MD, Anthony Makkinje, PhD

Blood (2006) 108 (11): 2608.

https://doi.org/10.1182/blood.V108.11.2608.2608

Published: 2006

Journal Articles

PDE-4 Inhibitor Rolipram Prevents Hypoxia Induced Pulmonary Hypertension in Transgenic Sickle Cell Sad Mice.

Lucia De Franceschi, MD, Giorgio Malpeli, Anne Janin, MD, Aldo Scarpa, MD, Christhophe Leboeuf, Orah Platt, MD, Philippe Leboulch, Emmanuel Payen, Yves Beuzard, MD, Carlo Brugnara, MD

Blood (2004) 104 (11): 3577.

https://doi.org/10.1182/blood.V104.11.3577.3577

Published: 2004

Journal Articles

PDE4 Inhibitors Augment Glucocorticoid-Mediated Apoptosis in B-CLL Cells in the Absence of Exogenous Adenylyl Cyclase Stimulation.

Adam Lerner, MD, Hongli Dong, PhD, Lewis Weintraub, MD, Paul M. Epstein, PhD, Sanjay Tiwari, PhD

Blood (2004) 104 (11): 4793.

https://doi.org/10.1182/blood.V104.11.4793.4793

Published: 2004

Journal Articles

Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis

Sanjay Tiwari, Kyriacos Felekkis, Eun-Yi Moon, Amanda Flies, David H. Sherr, Adam Lerner

Blood (2004) 103 (7): 2661–2667.

https://doi.org/10.1182/blood-2003-06-2154

Published: 2004

Journal Articles

PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A

Eun-Yi Moon, Adam Lerner

Blood (2003) 101 (10): 4122–4130.

https://doi.org/10.1182/blood-2002-10-3208

Published: 2003

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Cyclic-AMP Is an Actionable Novel Regulator of PD-L1 Expression in Untransformed Lymphocytes and Diffuse Large B Cell Lymphomas

Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies

Synergism Between PDE4 and PI3Kδ Inhibitors in DLBCL: Improved Clinical Activity with the Potential for Lower Toxicity

A Phosphodiesterase 4B-Mediated Interplay Between Tumor Cells and the Microenvironment Regulates Angiogenesis in B Cell Lymphoma

PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes

PDE4 Inhibitors Block TLR7 and TLR9-Driven Signaling, Proliferation and Cytokine Secretion in CLL Cells As Well As Proliferation Driven by Exposure to Apoptotic Cells

PDE4 Inhibitors Enhance DNA Damage-Induced Apoptosis In CLL

Control of the PI3K/AKT Pathway by Phosphodiesterase 4B Modulates Glucocorticoid Response in B-Cell Lymphomas.

Phosphodiesterase-4 Inhibition Reduces Ischemic/Reperfusion Liver Injury in a Mouse Model for Sickle Cell Disease.

Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.

PDE4 Inhibitors Augment Glucocorticoid Receptor Levels in B-CLL Cells but Not in T Cells, B Cells, Monocytes or Neutrophils.

PDE-4 Inhibitor Rolipram Prevents Hypoxia Induced Pulmonary Hypertension in Transgenic Sickle Cell Sad Mice.

PDE4 Inhibitors Augment Glucocorticoid-Mediated Apoptosis in B-CLL Cells in the Absence of Exogenous Adenylyl Cyclase Stimulation.

Among circulating hematopoietic cells, B-CLL uniquely expresses functional EPAC1, but EPAC1-mediated Rap1 activation does not account for PDE4 inhibitor-induced apoptosis

PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only